QuANTUM-First was a randomized, double-blind, placebo-controlled, phase 3 trial that compared quizartinib plus chemotherapy in newly diagnosed patients with FLT3 internal tandem duplication (ITD)-duplication-positive AML [19]. Here, FLT3 is linked to acute myeloid leukemia.